Last updated August 22, 2026
Key finding
Fiasp use resulted in a greater glucose reduction 120 minutes after Boost initialization [−59 ± 34 mg/dL vs −43 ± 31 mg/dL; P = .02].
This study analyzed the effects of ultra-rapid insulin in a hybrid closed-loop system, finding that Fiasp resulted in greater glucose reduction compared to insulin aspart.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Short-Term (≤3 mo)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
This study analyzed the effects of ultra-rapid insulin in a hybrid closed-loop system, finding that Fiasp resulted in greater glucose reduction compared to insulin aspart.
These findings are significant for diabetes management, particularly for patients using hybrid closed-loop systems. The greater glucose reduction observed with Fiasp could lead to improved glycemic control and potentially better health outcomes for individuals with diabetes, emphasizing the importance of selecting effective insulin therapies.
Effectiveness of the interventions remains unclear due to mixed results. Limited generalizability due to specific population characteristics. Potential for unmeasured confounders affecting outcomes.
Published in
Publication details and source links for this paper.
Chloë R, Charlotte B, Munachiso N, et al. The Use of Ultra-Rapid Insulin in a Hybrid Closed-Loop System: A Secondary Analysis. Journal of Diabetes Science and Technology. 2024;20(2):381-387. doi:10.1177/19322968241289963
Fiasp showed a mean glucose reduction of -59 ± 34 mg/dL compared to -43 ± 31 mg/dL for insulin aspart (P = .02).
Mean glucose on Boost initialization was 238 ± 62 mg/dL for Fiasp versus 218 ± 45 mg/dL for insulin aspart (P = .08).
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Fiasp, Insulin Lispro, Insulin aspart, and 1 more and Glucose reduction 120 minutes after Boost initialization, Mean glucose on Boost initialization.
This study contributes evidence to
Primary intervention
Fiasp
Primary outcomes
Primary intervention
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
0
Related topics
8
Evidence pairs
0
Related studies
Core evidence
The primary outcomes reported in this study.
Fiasp → Glucose reduction 120 minutes after Boost initialization
Fiasp → Glucose reduction 120 minutes after Boost initialization
Fiasp → Mean glucose on Boost initialization
Fiasp → Mean glucose on Boost initialization
Insulin aspart → Glucose reduction 120 minutes after Boost initialization
Insulin aspart → Glucose reduction 120 minutes after Boost initialization
Insulin aspart → Mean glucose on Boost initialization
Insulin aspart → Mean glucose on Boost initialization
Insulin Lispro → Glucose reduction 120 minutes after Boost initialization
Insulin Lispro → Glucose reduction 120 minutes after Boost initialization
Insulin Lispro → Mean glucose on Boost initialization
Insulin Lispro → Mean glucose on Boost initialization
Lyumjev → Glucose reduction 120 minutes after Boost initialization
Lyumjev → Glucose reduction 120 minutes after Boost initialization
Lyumjev → Mean glucose on Boost initialization
Lyumjev → Mean glucose on Boost initialization
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Fiasp and Glucose reduction 120 minutes after Boost initialization, Fiasp and Mean glucose on Boost initialization.
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Curated evidence collections and hubs this study is part of.
All studies on Fiasp
Contributes to Fiasp evidence base.
All studies measuring Glucose reduction 120 minutes after Boost initialization
Measures Glucose reduction 120 minutes after Boost initialization as a key outcome.
All studies measuring Mean glucose on Boost initialization
Measures Mean glucose on Boost initialization as a key outcome.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
1 results
1 results
1 results
1 results
1 results
Generated from the study's connected evidence using Evidence Intelligence™.
Fiasp appears to reduce glucose reduction 120 minutes after boost initialization.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Glucose reduction 120 minutes after Boost initialization
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Insulin Lispro appears to reduce glucose reduction 120 minutes after boost initialization.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Glucose reduction 120 minutes after Boost initialization
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Insulin aspart appears to reduce glucose reduction 120 minutes after boost initialization.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Glucose reduction 120 minutes after Boost initialization
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Lyumjev appears to reduce glucose reduction 120 minutes after boost initialization.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Glucose reduction 120 minutes after Boost initialization
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
